Sidewinder secures $137M to advance ‘precision’ ADCs
Source: BioPharma Dive - Latest News
Backed by OrbiMed, Novartis’ venture arm and many other investors, the biotech is among those working on newer technology that could broaden the reach of antibody-drug conjugates.